MyD88在卵巢癌组织中的表达及临床意义

摘要

目的 探讨髓性分化因子88(MyD88)在卵巢癌组织中的表达及其临床意义.方法 收集2000年8月至2010年2月在本院接受首次手术治疗的115例卵巢癌患者的肿瘤标本及癌旁正常卵巢组织标本,所有患者的诊断均经术后病理学检测结果证实,采用免疫组织化学方法检测MyD88蛋白在卵巢癌及癌旁正常组织中的表达,并探讨MyD88的表达量与卵巢癌患者临床病理特征和预后的相关性.结果 卵巢癌肿瘤组织标本中MyD88的阳性表达率为70.4％,卵巢癌旁正常组织中的阳性表达率为23.5％,两者相比差异有统计学意义(P＜0.05);此外,MyD88的阳性表达量与卵巢癌患者的年龄、肿瘤大小、组织学类型、有无腹水和病理学分级无关(P＞0.05),而与患者的有无淋巴结转移及临床分期相关(P＜0.05);MyD88阳性表达的卵巢癌患者五年生存率显著低于阴性表达的卵巢癌患者(P ＜0.001).结论 MyD88在卵巢癌组织中的表达显著升高,其可能在卵巢癌的发生、发展和侵袭中发挥重要作用.%Objective To examine the expression and clinical significance of MyD88 in ovarian carcinomas.Methods Specimens from 115 patients with ovarian carcinomas managed in our hospital between Augest 2000 and February 2010 were included in this study.Immunohistochemical staining was used to detect the expression of MyD88 in ovarian carcinomas and normal tissues.All the specimens were confirmed by pathology for ovarian carcinomas and normal tissues by HE staining.The correlation between the expression and clinical significance of patients was analyzed.Results The positive expression rate of MyD88 in ovarian carcinomas and normal tissues was 70.4％ and 23.5％,respectively.MyD88 expression was significantly associated with tumor stage and distant metastasis (P ＜ 0.05).According to the survival analysis of 115 ovarian carcinomas patients,cases in the MyD88 positive-expression group showed poorer overall survival rate when compared with negative-expression group (P ＜ 0.001).Conclusion These results indicate that the expression of MyD88 was related with in the progression of ovarian carcinomas and may have clinical utility in the prediction of prognosis of ovarian carcinomas.